24/7 Market News- Clinical Trial for Psilocybin Assisted Psychotherapy in Patients with Generalized Anxiety Disorder to Proceed following FDA Review of PsiGAD2 IND
DENVER, Colo., Aug 05, 2024 (247marketnews.com)- Incannex Healthcare Inc. (Nasdaq: IXHL) reported that it received approval from the US Food and Drug Administration (‘FDA’) to conduct the Company’s Investigational New Drug (‘IND’) opening Phase 2 clinical trial to investigate Incannex’s psilocybin pharmaceutical formulation, known as PSX-001, in conjunction with psychotherapy in patients with generalized anxiety disorder in the United States and the United Kingdom.
Incannex submitted the IND application to the FDA on 26 June 2024, which completed its review of the application package during the allocated 30-day period.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (IXHL)
- Today’s Top Performers: MoBot’s Market Review 08/26/25 06:00 AM
- MoBot alert highlights: NASDAQ: IXHL, NASDAQ: HKPD, NASDAQ: PFSA, NASDAQ: IVVD, NASDAQ: BENF (08/26/25 05:00 AM)
- Power Hour Push: Biotech, Blockchain, and Breakouts Set to Run into Afterhours
- Today’s Top Performers: MoBot’s Market Review 08/22/25 09:00 AM
- Biotech Rally Builds as Markets Eye Buybacks and Breakouts